Endocrinology25 Jul 2026
What Is an SGLT2 Inhibitor? Mechanism, Indications, and EvidenceRead article
Healthcare Sys & Biz7 Aug 2026
Prior Authorization: Why 'Fighting Back' Is Now Standard PracticeRead article
Metastatic pancreatic cancer: A new drug could shift your approach
The EMA granted accelerated assessment for an investigational medicine for metastatic pancreatic adenocarcinoma, potentially offering a new option in a difficult disease.
Jideytro offers new hope for ROS1-positive NSCLC after prior therapy
The FDA approved Jideytro for previously treated ROS1-positive non-small cell lung cancer, providing a new option for this rare subtype.
ARHGAP36: A new survival predictor for neuroblastoma patients
High ARHGAP36 levels predict improved 5-year survival in neuroblastoma patients, linking FOXC1-induced expression to altered Hedgehog signaling.
Why PARP inhibitors are changing the mCRPC treatment algorithm
Pluvicto's expanded approval: What it means for advanced prostate cancer
How non-animal models are redefining oncology drug safety
The real reason joint oncology practices need explicit protocols
Emotional support after cancer: What works for young adults?
Molecular Profiling Refines Salivary Gland Tumor Diagnosis
EHR data identifies liver transplant patients at high risk of early graft loss
An EHR-based marker accurately identifies liver transplant recipients at elevated risk of early graft failure and mortality, offering a tool for improved post-transplant management.
EHR-derived marker flags liver transplant recipients at high risk of early death
An EHR-based marker identifies liver transplant recipients at increased risk of 90-day mortality, offering a tool for pre-transplant risk stratification and post-operative management.
EHR data flags liver transplant patients at highest risk of post-op complications
An EHR-based marker identifies liver transplant recipients at high risk for adverse post-transplant outcomes, offering a tool for early intervention and personalised care strategies.
TNF emerges as a key node in autoimmune hepatitis, trial shows
Metabolic Dysfunction Associated Steatotic Liver Disease: An Overview
Coffee may cut liver disease risk, related mortality
Chronic Hepatitis Delta Virus: Why direct viral targeting matters now
Nearly 1 in 10 With Primary Biliary Cholangitis Have CKD
Liver Transplant Studies Retracted Over Organ Harvesting Concerns
Cardiovascular risk: Why men die earlier, women live sicker
Cardiovascular risk factors impact longevity and morbidity differently by sex, with men experiencing earlier mortality and women facing a longer duration of disease.
A Simpler Score for Coronary Calcium: Does it Help Predict Risk?
A simplified risk score may predict coronary artery calcium on CTA, potentially streamlining risk assessment for cardiovascular disease.
Pulsed Field Ablation: A New Frontier for Atrial Fibrillation?
Pulsed field ablation offers a novel, non-thermal approach to cardiac tissue destruction, leveraging irreversible electroporation for targeted cell death in arrhythmias.
Severe VT in ischaemic cardiomyopathy: Why current care isn't enough
Smartphones and Pacemakers: Separating Fact from Electromagnetic Fiction
Safe caffeine intake does not harm heart health
Heart Failure Treatment in 2026: A Clinical Overview
How lipid packing dictates caveolae stability at the plasma membrane
For atrial fibrillation, integrated pathways may beat individual fixes
GLP-1s reduce inflammation in adults without diabetes
GLP-1 receptor agonists lower C-reactive protein levels in adults without diabetes, indicating a potential anti-inflammatory effect beyond glucose control.
Why lifestyle advice alone still dominates obesity searches
Despite advances in pharmacotherapy, Google searches for obesity management remain heavily skewed towards lifestyle interventions, indicating a persistent public perception.
Chiglitazar: Is a 'pan' approach better for MASLD?
Chiglitazar, a PPAR pan-agonist, significantly reduced liver fat content and improved insulin sensitivity in MASLD patients with hypertriglyceridemia.
What Is an SGLT2 Inhibitor? Mechanism, Indications, and Evidence
GLP-1s and lifestyle: a new path to stronger bones?
Setmelanotide curbs insatiable hunger in acquired hypothalamic obesity
CGM offers tighter glucose control for type 2 diabetes on dialysis
Weekly growth hormone therapy: a safer path to long-term height gains?
Your obesity patients deserve more than just weight loss goals
Ecopipam for Tourette Syndrome: Did it deliver on its promise?
Ecopipam significantly reduced tic severity in Tourette syndrome patients, but its safety profile warrants careful consideration for long-term use.
Beyond screen time: How short videos rewire dopamine pathways
The pervasive use of short-form video content raises questions about its impact on attention spans and cognitive processing, particularly in younger populations.
Football Headers Linked to Cognitive Decline, Neurodegeneration
Repeated head impacts from football headers correlate with increased risk of cognitive impairment and neurodegenerative disease, particularly in former professional players.
Chronic Migraine: Is the Gut-Brain Axis the Missing Link?
The long shadow of head trauma: sport, CTE, and dementia risk
Repeated head impacts: What they mean for dementia risk
Pupil Dilation: A Window into Synesthesia's Perceptual Quality
Biomarkers hint at who recovers motor function after stroke
Roche Halts Huntington's Gene-Silencing Programs
The largest unmet need in cardiology finally has a multi-drug evidence base
Amivantamab plus lazertinib vs osimertinib: a survival benchmark four years in the making
Resmetirom changed everything. Now the race is on for combination therapies and broader eligibility
12 FDA-approved JAK inhibitors, updated EULAR guidelines, and the TYK2 era beginning
From G12C to pan-RAS: the mutation-by-mutation guide to the KRAS revolution
Multiple MyelomaThe Neutropenic Diet: An Unnecessary Burden for Leukemia and Transplant Patients?
Get the full storyRNR inhibition reverses FLT3i resistance in AML, prolonging survival
Get the full storyAsciminib: A new first-line option for chronic myeloid leukemia?
Get the full storyWhat Is CAR-T Cell Therapy? Mechanism, Approved Indications, and Key Evidence
Get the full storyDonor T-cells prevent CMV complications in blood cancer patients
Get the full storyMAHA Monday: The Rush to Publish and Its Clinical Fallout
Get the full storyLiso-Cel Delivers Durable OS Benefit in R/R LBCL, Redefining Treatment
Get the full storyNew Regimen Confers 'Meaningful' Benefit in Aggressive Lymphoma
Get the full storyFDA Expands Casgevy for Sickle Cell in Children 2 Years and Older
Get the full storyMonoclonal Antibodies May Complicate Transfusion Testing
Get the full story
Arthritis Rheumatoid
Clostridioides difficileFrailty, not just RA, predicts osteoporotic fracture risk
Enpatoran gets breakthrough tag for lupus: Another IFN-I inhibitor enters the fray
Get the full storyInfluenza treatment: The single-dose option challenges multi-day adherence
Get the full story
AdvertisementAdvertisementAdvertisement
• Aug 28 – 31ERS 2026 • Barcelona, ES 
• Sep 5 – 9EASD 2026 • Milan, IT 
• Sep 28 – Oct 2UEG Week 2026 • Vienna, AT 
• Oct 3 – 7Joint ACTRIMS-ECTRIMS 2026 • Toronto, CA 
• Oct 21 – 23ESMO 2026 • Madrid, ES • Oct 23 – 27AHA 2026 • Chicago, US 
• Nov 7 – 9ACR 2026 • Washington DC, US • Nov 14 – 19ASH 2026 • New Orleans, US • Dec 12 – 15ACC.27 Together With WCC • Houston, US • Apr 10 – 12ESC 2026 • Munich, DE • Aug 28 – 31ERS 2026 • Barcelona, ES • Sep 5 – 9EASD 2026 • Milan, IT • Sep 28 – Oct 2UEG Week 2026 • Vienna, AT • Oct 3 – 7Joint ACTRIMS-ECTRIMS 2026 • Toronto, CA • Oct 21 – 23ESMO 2026 • Madrid, ES • Oct 23 – 27AHA 2026 • Chicago, US • Nov 7 – 9ACR 2026 • Washington DC, US • Nov 14 – 19ASH 2026 • New Orleans, US • Dec 12 – 15ACC.27 Together With WCC • Houston, US • Apr 10 – 12
Advertisement
BostonJun 13 – 16 2026
Low Alkaline Phosphatase: Recognizing Clinical Consequences
Low alkaline phosphatase (ALP) is often overlooked, but its clinical consequences, particularly hypophosphatasia, warrant increased diagnostic vigilance.
Endocrinologists' Role in Early Thyroid Eye Disease Recognition
Early recognition of thyroid eye disease (TED) by endocrinologists is critical for optimal patient outcomes, enabling timely intervention.
Classic CAH: New Approaches to Glucocorticoid Dosing
Endocrinology specialists are re-evaluating glucocorticoid dosing strategies for classic congenital adrenal hyperplasia (CAH), focusing on individualised regimens to balance androgen control and minimise adverse effects.
Afirma Molecular Testing: Unique Situations and New Prognostic Development
Afirma molecular testing aids thyroid nodule management, particularly in indeterminate cytology. New prognostic markers enhance risk stratification.
Desmopressin Dosing Refined for Central Diabetes Insipidus
New insights into desmopressin administration for central diabetes insipidus (CDI) aim to optimise efficacy and minimise hyponatremia risk.
GLP-1 RAs Reduce CV Risk in T2D Via Weight, Glucose Pathways
GLP-1 receptor agonists offer cardiovascular risk reduction in type 2 diabetes through both weight loss and direct glucose-lowering mechanisms.
Defining Hyperphagia Treatment Possibilities in Prader-Willi Syndrome
Clinician and caregiver perspectives highlight the complex challenges and unmet needs in managing hyperphagia in Prader-Willi Syndrome.
Liver-Directed Treatment Shows Efficacy in Metabolic Dysfunction
A novel liver-directed treatment presented at endo 2026 offers a targeted approach for metabolic dysfunction, addressing a significant unmet clinical need.
Hypoparathyroidism Treatment: Patient, Care Partner, HCP Perspectives
New perspectives on hypoparathyroidism treatment from patients, care partners, and HCPs highlight unmet needs and treatment goals.
Severe Hypoglycemia in T1D: Enhancing Patient-Clinician Dialogue
Addressing severe hypoglycemic events in type 1 diabetes requires direct, empathetic clinician-patient conversations to improve management and outcomes.
XLH Adults: Osteomalacia Persists Despite Conventional Therapy
Adults with X-linked hypophosphatemia (XLH) frequently experience persistent osteomalacia, even with conventional phosphate and active vitamin D treatment.
Cushing's Syndrome: Addressing Diagnostic Delays and Treatment Gaps
Cushing's syndrome presents a diagnostic challenge, often leading to significant delays in treatment initiation and suboptimal patient outcomes.
Korlym® for Cushing's Syndrome: Patient Experience, Side Effects and 2026 Clinical Data
Patient-reported outcomes from Endo 2026 show Korlym® (mifepristone) cuts weight gain, fatigue and mood disturbances in Cushing's syndrome. Covers mechanism of cortisol receptor blockade, side effect profile, and how it compares to relacorilant.
12 Months of Romosozumab Builds Bone Density in Postmenopausal Osteoporosis
A 12-month course of romosozumab significantly increases bone mineral density in postmenopausal women with osteoporosis.
Hypothyroidism: Symptom Burden Persists Despite Euthyroidism
Many patients with hypothyroidism report persistent symptoms despite achieving biochemical euthyroidism, highlighting a significant symptom-treatment gap.
Endo 2026: Risk-Based Osteoporosis Management Refines Clinical Practice
Endo 2026 highlighted refined risk-based strategies for osteoporosis care, advocating for tailored interventions beyond universal guidelines to improve patient outcomes.
Hypercortisolism: Emerging Diagnostic and Management Insights
New evidence presented at Endo 2026 refines our understanding of hypercortisolism, impacting diagnostic strategies and therapeutic approaches.
Obesity Care: Tailored Treatment Strategies Highlighted at endo 2026
Personalised treatment approaches for obesity, moving beyond a 'one-size-fits-all' model, were a key focus at endo 2026.
Acromegaly Management: Focus on Biochemical Control at ENDO 2026
New insights from ENDO 2026 highlight the persistent challenges in achieving biochemical control for acromegaly patients.
Steroidogenesis Inhibitor Targets Root Cause of Cushing’s Syndrome
A novel steroidogenesis inhibitor presented at ENDO 2026 offers a targeted approach to endogenous Cushing's syndrome by reducing cortisol overproduction.
Peer Insights on Once-Daily Weight Management Therapy at endo 2026
Endocrinology specialists discussed the clinical utility of a once-daily treatment for weight management in appropriate adult patients.
Desiccated Thyroid Extract: Efficacy and Safety in Hypothyroidism
A case-based discussion at endo 2026 reviewed the role of desiccated thyroid extract (DTE) in hypothyroidism management, highlighting patient selection and comparative efficacy.
Low Alkaline Phosphatase: Recognizing Clinical Consequences
Low alkaline phosphatase (ALP) is often overlooked, but its clinical consequences, particularly hypophosphatasia, warrant increased diagnostic vigilance.
Endocrinologists' Role in Early Thyroid Eye Disease Recognition
Early recognition of thyroid eye disease (TED) by endocrinologists is critical for optimal patient outcomes, enabling timely intervention.
Classic CAH: New Approaches to Glucocorticoid Dosing
Endocrinology specialists are re-evaluating glucocorticoid dosing strategies for classic congenital adrenal hyperplasia (CAH), focusing on individualised regimens to balance androgen control and minimise adverse effects.
Afirma Molecular Testing: Unique Situations and New Prognostic Development
Afirma molecular testing aids thyroid nodule management, particularly in indeterminate cytology. New prognostic markers enhance risk stratification.
Desmopressin Dosing Refined for Central Diabetes Insipidus
New insights into desmopressin administration for central diabetes insipidus (CDI) aim to optimise efficacy and minimise hyponatremia risk.
GLP-1 RAs Reduce CV Risk in T2D Via Weight, Glucose Pathways
GLP-1 receptor agonists offer cardiovascular risk reduction in type 2 diabetes through both weight loss and direct glucose-lowering mechanisms.
Defining Hyperphagia Treatment Possibilities in Prader-Willi Syndrome
Clinician and caregiver perspectives highlight the complex challenges and unmet needs in managing hyperphagia in Prader-Willi Syndrome.
Liver-Directed Treatment Shows Efficacy in Metabolic Dysfunction
A novel liver-directed treatment presented at endo 2026 offers a targeted approach for metabolic dysfunction, addressing a significant unmet clinical need.
Hypoparathyroidism Treatment: Patient, Care Partner, HCP Perspectives
New perspectives on hypoparathyroidism treatment from patients, care partners, and HCPs highlight unmet needs and treatment goals.
Severe Hypoglycemia in T1D: Enhancing Patient-Clinician Dialogue
Addressing severe hypoglycemic events in type 1 diabetes requires direct, empathetic clinician-patient conversations to improve management and outcomes.
XLH Adults: Osteomalacia Persists Despite Conventional Therapy
Adults with X-linked hypophosphatemia (XLH) frequently experience persistent osteomalacia, even with conventional phosphate and active vitamin D treatment.
Cushing's Syndrome: Addressing Diagnostic Delays and Treatment Gaps
Cushing's syndrome presents a diagnostic challenge, often leading to significant delays in treatment initiation and suboptimal patient outcomes.
Korlym® for Cushing's Syndrome: Patient Experience, Side Effects and 2026 Clinical Data
Patient-reported outcomes from Endo 2026 show Korlym® (mifepristone) cuts weight gain, fatigue and mood disturbances in Cushing's syndrome. Covers mechanism of cortisol receptor blockade, side effect profile, and how it compares to relacorilant.
12 Months of Romosozumab Builds Bone Density in Postmenopausal Osteoporosis
A 12-month course of romosozumab significantly increases bone mineral density in postmenopausal women with osteoporosis.
Hypothyroidism: Symptom Burden Persists Despite Euthyroidism
Many patients with hypothyroidism report persistent symptoms despite achieving biochemical euthyroidism, highlighting a significant symptom-treatment gap.
Endo 2026: Risk-Based Osteoporosis Management Refines Clinical Practice
Endo 2026 highlighted refined risk-based strategies for osteoporosis care, advocating for tailored interventions beyond universal guidelines to improve patient outcomes.
Hypercortisolism: Emerging Diagnostic and Management Insights
New evidence presented at Endo 2026 refines our understanding of hypercortisolism, impacting diagnostic strategies and therapeutic approaches.
Obesity Care: Tailored Treatment Strategies Highlighted at endo 2026
Personalised treatment approaches for obesity, moving beyond a 'one-size-fits-all' model, were a key focus at endo 2026.
Acromegaly Management: Focus on Biochemical Control at ENDO 2026
New insights from ENDO 2026 highlight the persistent challenges in achieving biochemical control for acromegaly patients.
Steroidogenesis Inhibitor Targets Root Cause of Cushing’s Syndrome
A novel steroidogenesis inhibitor presented at ENDO 2026 offers a targeted approach to endogenous Cushing's syndrome by reducing cortisol overproduction.
Peer Insights on Once-Daily Weight Management Therapy at endo 2026
Endocrinology specialists discussed the clinical utility of a once-daily treatment for weight management in appropriate adult patients.
Desiccated Thyroid Extract: Efficacy and Safety in Hypothyroidism
A case-based discussion at endo 2026 reviewed the role of desiccated thyroid extract (DTE) in hypothyroidism management, highlighting patient selection and comparative efficacy.
